9.17.12-Base Pair Founder & Chief Scientist, Dr. Bill Jackson will direct a new 2 year contract from the National Cancer Institute entitled, “Development of Alternative Affinity Capture Reagents for Cancer Proteomics Research“. Under the contract which is formally placed with Base Pair’s parent company, BioTex, Inc., novel aptamers to at least 75 selected cancer biomarker proteins will be developed. The contracted aptamers will be developed utilizing the same patented technology used for all protein projects at Base Pair. The resulting aptamers are expected to have considerable value to the cancer research community and aptamers will be made available for research purposes as they are validated at Base Pair Biotechnologies Existing Aptamers